Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

Vandana Singh
1 min read
0
In this article:

  • Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder.

  • ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data.

  • 89% (319/359) of patients met the consensus threshold of SABA reliever medication use, and 72% (260/359) met the threshold of SABA reliever medication use ≥200% above baseline.

  • Also Read: BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal.

  • 17% (62/359) of patients made 25 or more valid inhalations in a week, a level associated with unanimous consensus of likely impending or ongoing exacerbation.

  • 29% (104/359) of the patients exhibited a rate of SABA reliever use over 12 weeks, equivalent to three or more canisters per year.

  • Concurrently, Teva received the U.K. approval for Ongavia, a biosimilar to Lucentis (ranibizumab ), an eye injection, for neovascular (wet) age-related macular degeneration.

  • Lucentis is marketed by Genentech, a unit of Roche Holdings AG (OTC: RHHBY).

  • Price Action: TEVA shares are up 6.51% at $8.43 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories